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Injectability
Antibiotic
Drug release
Delivery systemThe introduction of an antibiotic, sodium fusidate (SF), into the liquid phase of calcium carbonate–calcium phos-
phate (CaCO3–CaP) bone cement was evaluated, considering the effect of the liquid to powder ratio (L/P) on the
composition and microstructure of the set cement and the injectability of the paste. In all cases, we obtained set
cements composedmainly of biomimetic carbonated apatite analogous to bonemineral.With this study, we evi-
denced a synergistic effect of the L/P ratio and SF presence on the injectability (i.e., the ﬁlter-pressing pheno-
menon was suppressed) and the setting time of the SF-loaded cement paste compared to reference cement
(without SF). In addition, the in vitro study of SF release, according to the European Pharmacopoeia recommen-
dations, showed that, regardless of the L/P ratio, the cement allowed a sustained release of the antibiotic over
1month in sodium chloride isotonic solution at 37 °C and pH 7.4; this release is discussed considering themicro-
structure characteristics of SF-loaded cements (i.e., porosity, pore-size distribution) before and after the release
test. Finally, modelling antibiotic release kineticswith severalmodels indicated that the SF releasewas controlled
by a diffusion mechanism.1. Introduction
Post-operative infection is one of themajor causes of increasedmor-
bidity and themost serious and costly complications associatedwith or-
thopaedic procedures. Besides, the infected areas are often difﬁcult to
reach and treat. The development of minimally invasive surgical tech-
niques that are able to control and reduce this post-operative risk and
pain has promoted the use of injectable biomaterials, especially for or-
thopaedic applications [1–2]. Despite the reduction in post-surgery
risks associated with the use of minimally invasive surgery techniques,
new biomaterials have been developed for therapeutic purposes. These
materials are capable of releasing a drug over a long period that could
prevent or treat some postoperative complications. Calcium phosphate
cements (CPCs) have great potential as carriers for the controlled re-
lease of drugs in bone tissue, owing to their composition that is close
to bone mineral, excellent bioactivity and possible use as injectable
and degradable grafting materials. They are set at low temperatures
(ambient or physiological temperatures), which enables the association
of CPCs with biologically active molecules, for example during paste
preparation, without denaturation of the molecule or loss of its thera-
peutic activity. Several studies have been conducted on the associationEmileMonso, CS 44362, 31030
es).of antibiotics, such as gentamicin, cephalexin, doxycycline or vancomy-
cin with CPCs in order to prevent implant-associated infection or to
treat speciﬁc infections [3–10].
Usually, surgeons implement a prophylactic antibiotherapy by means
of oral administration in order to prevent or reduce infectious pathologies
after a surgery. The mostly used antibiotics in orthopaedic or
traumatology are cefazolin, vancomycin, gentamycin and ciproﬂoxacin,
but other antibiotics with good bone-tissue penetration (N30%), such as
rifampicine, fosfomycine or fusidic acid, are also proposed [11–14]. In
the present study, we chose a water-soluble derivative of fusidic acid, so-
dium fusidate (SF),which showed broad spectrumbactericidal and fungi-
cidal properties in addition to very good bone penetration [14].
The performance of CPCs in association with an antibiotic to design
drug-delivery systems is related to speciﬁc parameters, that is, the ce-
ment microstructure (i.e., porosity, tortuosity and speciﬁc surface
area) and its resorbability, aswell as the solubility of the drug and its in-
teractions with the mineral matrix. An overview of the combination of
pharmaceutical and biological substances with CPCs for delivery appli-
cations, in addition to the effect of the principle-loading method on
the physicochemical properties of the cements, has been reported by
Ginebra et al. [10].
The objective of this work is to study the physicochemical properties
of biomimetic apatite cement loaded with an antibiotic, sodium fusidate,
which is a soluble salt of fusidic acid. We aim to evaluate the characteris-
tics and properties of the paste (i.e., setting time and injectability) and the
set cement (i.e.,mechanical and drug-release properties) in a view to pro-
pose a sustained drug-release biomimetic bone substitute material.
2. Materials and methods
2.1. Preparation and characterisation of the cements
The reactive powders (solid phase) were comprised of vaterite cal-
cium carbonate (CaCO3) and dicalcium phosphate dihydrate (DCPD;
CaHPO4·2H2O), which were prepared by precipitation at ambient tem-
perature, as previously described [15]. The cements investigated in this
study were obtained by mixing the reactive powders (DCPD and
vaterite in a 1:1 weight ratio) with an appropriate amount of liquid
phase. The reference cement (CR) was produced using pure water
only as the liquid phase, whereas we used a 9 wt.% SF aqueous solution
to prepare the antibiotic-loaded cements (CSF). The liquid-to-powder
ratios (L/P) used to prepare the cement pastes were 0.7 and 0.8 mL/g,
leading to reference cements named CR7 and CR8, and to antibiotic-
loaded cements referred to as CSF7 and CSF8, respectively. L/P = 0.7
corresponds to theminimum amount of liquid phase (water or aqueous
solution of SF) to be added to the powder to form amalleable paste after
mixing. We also chose to work with a higher L/P ratio (0.8) which cor-
responds to a compromise between improvement of the injectability
of the paste while adding minimum amount of water to keep the ce-
ment mechanical properties as high as possible.
After mixing the solid with the liquid phase, the obtained paste was
placed in a sealed container saturated with H2O at 37 °C for setting and
hardening for 2 days.
The set and dried cements were characterised by X-ray diffraction
(INEL CPS 120 diffractometer) using a Co anticathode (wavelength =
1.78897 Å), transmission Fourier transform infrared spectroscopy with
KBr pellets (Nicolet 5700 spectrometer, ThermoElectron) and scanning
electron microscopy (SEM LEO 435 VP). Porosity measurements (be-
tween 5 nm and 360 μm) were performed using mercury intrusion
porosimetry (AutoPore III, Micromeritics).
2.2. Setting time determination
The setting time of the cement paste was determined at 37 °C. The
initial and ﬁnal setting times were estimated according to a protocol
adapted from the ASTM C266-03 and ISO 9917-1:2007 standards,
using a Gillmore needle apparatus (HM-310, Gilson Inc.). Brieﬂy, the
system comprised two stainless steel needles: one is 2.13mmdiameter
and 113.4 g weight used to determine the initial setting time; the sec-
ond is 1.06 mm diameter and 453.6 g weight applied to estimate the
ﬁnal set. When the needles did not lead to a trace on the upper surface
of the cement paste, the values of setting time were determined
(expressed inminutes fromwhen themixingbegan). Allmeasurements
were performed in triplicate.
2.3. Mechanical properties of the hardened cements
A cement paste, prepared as described above, was introduced into
cylindrical moulds (10 mm in diameter and 20 mm in height), which
were then placed in sealed containers saturated with water at 37 °C
for setting and hardening. After 2 days, the hardened cement waswith-
drawn from the mould and left to dry for 1 week at 37 °C. Five cements
were prepared for each of the tested cement formulations. The com-
pressive strength of the cylindrical cement blocks was evaluated using
a Hounsﬁeld Series S apparatus.
2.4. Injectability of the cement paste
The injectability of the reference and antibiotic-loaded cement
pastes was measured at room temperature using a TAXT2 texture
analyser (Stable Micro Systems) equipped with a speciﬁc syringesystem, including a 2.5 mL syringe (inner diameter of the syringe
body was 9 mm and the opening/exit diameter was 2 mm) without a
needle. The protocol consists of measuring the force, expressed as a
load to be applied on the piston (piston surface = 64 mm2), to extrude
a volume of paste corresponding to the displacement of 15 mm of the
syringe piston at a constant rate (2 mm·s−1).
Brieﬂy, the syringewas ﬁlled with cement paste and the injectability
measurement was performed 5 min after paste preparation (t = 0 cor-
responds to the beginning of powder –liquid mixing). This period cor-
responds to the time needed to prepare the paste, to introduce it into
the syringe and to place the syringe system on the texture analyser be-
fore starting the injectability measurements. This period could also cor-
respond to the time a surgeon would need to prepare the cement paste
and to introduce it into a device for implantation using a minimally in-
vasive technique.
2.5. Antibiotic release study
The study of the antibiotic release from the cement was performed
in vitro, according to the European Pharmacopoeia recommendations,
using a Dissolutest (Pharmatest®) equipped with a stirring system (ro-
tating paddle rate = 100 rpm) adapted to a series of 12 bowls (1 L),
which allows homogenisation of the solution composition throughout
the test.
The cement samples were prepared as described above for the me-
chanical properties determination of hardened cements, except for the
cylindrical mould dimensions, which were smaller so as to consume
less of the cement paste (17.5 mm diameter × 10 mm height). Then,
in order to study the drug-release kinetics, the cement blocks were im-
mersed in 1 L of 0.9% (w/w) NaCl solution at physiological pH (pH =
7.4) and 37 °C under sink conditions for 5weeks. The surface of each ce-
ment block in contact with the release solutionwas equal and limited to
the top of the cylindrical block (S = 2.40 cm2).
Some (10 mL) of the solution was removed from each bowl every
day and replaced with the same volume of fresh 0.9% (w/w) NaCl solu-
tion at pH = 7.4 in order to maintain a constant solution/cement ratio
throughout the experiment duration (i.e., 1 month). The pH value of
the aliquot removed each day was not recorded but the pH value of
theNaCl solution after 5weeks of release testwas around 8.0; this slight
increase could be attributed to the release of carbonate species from the
cement in the medium. The sampled solution was immediately ﬁltered
using a Millipore ﬁlter (pore diameter of 0.2 μm) to eliminate any ﬁne
particles that could be released from the cement block and impair the
titration of the release solution by UV spectrophotometry. The concen-
tration of the antibiotic in the sampled solution was then determined
by UV spectrophotometry (UV-1800 SHIMADZU) at 235 nm. The ab-
sence of interference (no absorbance)was checked for the reference ce-
ment using the same electrolyte solution.
3. Results
3.1. Cement composition and microstructure
The X-ray diffraction patterns of the cement prepared in the absence
(CR7) or presence of sodium fusidate (CSF7) are presented in Fig. 1. The
XRD pattern of the reference cement (CR7) showed that it was com-
posed of carbonate apatite and residual vaterite, revealing the formation
of apatite through the reaction of part of the vaterite with all of the
DCPD powder. The results also indicated that adding SF to the cement
paste did not signiﬁcantly affect the end product, as the XRD patterns
of both cements are similar. FTIR spectrum of drug containing cement
(CSF) compared to the spectrum of the reference cement (CR) con-
ﬁrmed that addition of drug into cement did not change signiﬁcantly
the composition of cement ﬁnal composition despite the presence of
the drug (Fig. 2). However FTIR spectroscopy allowed to identify on
CSF spectrum bands of very low intensity, which are characteristic of
Fig. 1. X-ray diffraction patterns of the cements prepared with L/P= 0.7 for (a) the refer-
ence cement and (b) SF-loaded cement, compared to the XRD patterns of the reactive
powders (c) vaterite and (d) brushite.
Fig. 2. FTIR spectra of sodium fusidate (SF), vaterite (V), reference cement (CR), and SF-
loaded cement (CSF).sodium fusidate: at 1265 cm−1 (ester C\\O), 1720 cm−1 (acid C_O)
and 2845–3000 cm−1 (C\\H).
Fig. 3 shows the SEM micrographs of the reactive powders (Fig. 3a
and b for brushite and vaterite, respectively) and reference and
antibiotic-loaded cements (Fig. 3c and d, respectively). We can observe
a microporous microstructure for both hardened cements (Fig. 3c and
d). In addition, the typical ﬁne plate-likemorphology of nanocrystalline
apatitewas clearly visiblewhereas thebrushite platelet crystalswere no
more visible in both hardened cement micrographs. Furthermore, as
vaterite particles showed lentil-like shape with a mean size of about
2–3 μm (Fig. 3b); it seems that these particles served as a support
for nanocrystalline apatite nucleation and growth, as we can see
nanocrystals of apatite covering the surface of quite spherical particles
of about 2–3 μm in diameter (Fig. 3c and d). Finally, we can see that
the morphology of the apatite and vaterite crystals and their arrange-
ment did not appear to be altered by the introduction of sodium fusidate
in the cement formulation.Fig. 3. SEM micrographs of (a) brushite and (b) vaterite powders (scale bar = 10 μm) and of tWecan further analyse themicrostructure of the cement by examin-
ing the porosity measurements performed on the reference and SF-
loaded cements. The obtained results are summarised in Table 1. The ce-
ments exhibit a total porosity ranging between 69 and 85% depending
on the formulation (i.e., the L/P ratio and the presence or absence of an-
tibiotic). As expected, we can see that an increase in L/P from 0.7 to 0.8
enhanced the cement total porosity: for the reference cement, an aug-
mentation in the total porosity of 11%was observedwhereas a lower in-
crease in total porosity (5%)was observedwhen increasing the L/P ratio
for the cements loaded with the antibiotic (Table 1). If the increase in
the cement total porosity appears also determined by the presence of
the drug, the increase of submicron-size porosity, seems however only
related to the L/P ratio used. Indeed, whatever the considered cement
(CR or CSF) submicron-size porosity increases of 10% when the amount
of water used for the preparation of the cement paste increases of 14%
(from an L/P of 0.7 to 0.8).
In addition whatever the L/P ratio, the proportion of smaller pores
(submicron porosity: 5 nm–2 μm), which represents the majorhe reference (c) and SF-loaded (d) cements (scale bar = 1 μm) prepared with L/P = 0.8.
Table 1
Total porosity and microporosity of the reference (CR) and SF-loaded (CSF) cements pre-
pared with different L/P ratios (0.7 or 0.8).
Reference cement (CR) Sodium fusidate-loaded
cement (CSF)
L/P = 0.7 L/P = 0.8 L/P = 0.7 L/P = 0.8
Total porosity (%)
[5 nm–300 μm]
74 ± 2 85 ± 3 69 ± 1 74 ± 1
Submicron porosity (%)
[5 nm–2 μm]
70 ± 2 80 ± 3 63 ± 2 72.7 ± 0.4contribution (91 to 98%) in the total porosity of the studied cementswas
lower for SF-loaded cements. Indeed, the addition of the drug into ce-
ment induces a decrease of 7% of the submicron porosity. This decrease
could be related to the ﬁlling of the pores and voids with the antibiotic.
Furthermore, if we examine the pore-size distributions for the reference
cements (L/P = 0.7 and 0.8) presented in Fig. 4a, the presence of two
types of pore sizes within both cements can clearly be distinguished;
theﬁrst group of pore sizes ranged between 7 and 60 μmand represent-
ed a very small pore volume (b4% of the total porosity of the cement),
whereas the second group of pore sizes ranged between 5 and
200 nm and represented around 95% of the total porosity of the refer-
ence cements for both L/P ratios tested. The increase in L/P induced a
slight increase in the submicron-pores size (i.e., the peak between 5
and 150 nm slightly shifted towards higher pore size;maximum shifted
from 16 to 21 nm), indicating the determinant role of water in the po-
rosity and microstructure of the cement. The pore-size distribution of
SF-loaded cements (Fig. 4b) appears to be signiﬁcantly different from
that of the reference cements, and is also determined by the L/P ratio.
We observed a broader range of submicron-pore sizes for the SF-
loaded cements than for the reference cements; this broadening is
more pronounced for higher L/P ratios, and pores with sizes ranging be-
tween 1 and 20 μm are created.
These observations conﬁrmed that, not only the amount of water
(L/P ratio), but also the presence of sodium fusidate were determi-
nant parameters for the cement microstructure.3.2. Cement paste setting time
The measured setting times for cements prepared with different L/P
ratios in the presence or absence of antibiotic are reported in Table 2.
The increase in L/P ratio affected both the initial and ﬁnal setting
times of both types of cements studied. Thus, when the L/P ratio in-
creased from 0.7 to 0.8, the initial setting time (tI) increased from 75
to 96 min for the reference cement and from 50 to 65 min for
antibiotic-loaded cement.
In addition, the incorporation of sodium fusidate into the cement in-
duced a decrease in the initial setting time for both L/P ratios tested: tI
decreased from 75 to 50 min for L/P = 0.7 and from 96 to 65 min for
L/P=0.8. A similar evolution occurred for the ﬁnal setting timewith re-
spect to L/P ratio and drug incorporation.Table 2
Initial and ﬁnal setting times of reference (CR) and SF-loaded (CSF) cements prepared
with different L/P ratios (0.7 or 0.8).
Cements Initial setting time (tI)
(min)
Final setting time (tF)
(min)
L/P = 0.7 L/P = 0.8 L/P = 0.7 L/S = 0.8
CR7 75 ± 2 – 150 ± 4 –
CR8 – 96 ± 3 193 ± 2
CSF7 50 ± 2 – 105 ± 3 –
CSF8 – 65 ± 2 – 130 ± 33.3. Cement compressive strength
The effect of the L/P ratio and the introduction of sodium fusidate on
the compressive strength of the cements are presented on Fig. 5. As gene-
rally observed, the compressive strength decreased signiﬁcantly when
the L/P increased from 0.7 to 0.8. The presence of the antibiotic in the
cement slightly decreased the compressive strength of the cement from
11.8 to 9.3 MPa for L/P = 0.7 and from 4 to 3.4 MPa for L/P = 0.8. How-
ever, this decrease does not appear signiﬁcant in the latter case.
3.4. Paste injectability
Fig. 6 shows that the injectability of the reference cements (CR7 and
CR8) was poor, as the load needed to extrude the volume of paste in-
creased during piston displacement by up to 21 kg for L/P = 0.7. The
two curves obtained were characteristic of the occurrence of a ﬁlter-
pressing phenomenon during paste extrusion. Interestingly, the ﬁlter-
pressing phenomenonwasmuch less pronounced for SF-loaded cement
pastes, as the two curves were ﬂatter and themaximum load needed to
extrude the paste was 6.8 kg for L/P = 0.7. These results indicated that
antibiotic-loaded cement pastes were injectable, as the load needed to
extrude the paste was less than 12 kg in all cases, which is the accepted
limit of manual injectability. The injectability of the paste was signiﬁ-
cantly improved by an increase in the L/P ratio in all cases.
3.5. Kinetics of antibiotic release
The release of fusidate from the cements is presented in Figs. 7 and 8
as a cumulative percentage of fusidate released and as the amount of
fusidate released per day in 1 L of NaCl solution as a function of time,
respectively.Fig. 4. Pore-size distribution of the reference (a) and the SF-loaded (b) cements, both pre-
pared with L/P ratios of 0.7 and 0.8.
Fig. 5. Compressive strength of the reference (CR) and the SF-loaded (CSF) cements, both
prepared with different L/P ratios of 0.7 and 0.8.
Fig. 6. Inﬂuence of the L/P ratio and the presence of sodium fusidate on the injectability of
the cement paste.The sustained release of the antibiotic was evidenced over more
than 1 month (between 20 and 30% released at day 30), no matter
what the L/P ratio (Fig. 7). The release rate was signiﬁcantly faster for
cement preparedwith the highest L/P ratio. The release rate can be eva-
luated by considering the time required to release 20% (t20%) of the so-
dium fusidate; thus, 27 days was the necessary time to release 20% of
the antibiotic from CSF7 cement, whereas it took only 12 days for the
CSF8 cement to reach the same rate of release (20% of the drug re-
leased). Finally, at the end of the test (day 34), the cumulated SF release
was about 30 and 22% from CSF8 and CSF7 cements, respectively.
The dissolution proﬁles (CSF7 and CSF8) highlight an initial burst re-
lease of fusidate (3–10 mg/day) during the ﬁrst days (Fig. 8), but then
the daily SF release signiﬁcantly decreased until a sustained and quite
constant release rate was achieved (1–2 mg/day).
4. Discussion
Generally, the addition of a drug to bone cement formulation mod-
iﬁes the physicochemical properties of the material; besides, drug re-
lease is deﬁned by speciﬁc parameters, that is, the porosity of the
matrix, solubility of the drug and its interactionwith the cement. The ef-
fects of the L/P ratio and antibiotic loading on the physicochemical pro-
perties andmicrostructure of the cement andon the drug-release ability
have been identiﬁed through the presented results. Hereafter, the vari-
ous parameters controlling the cement properties and the mechanism
of antibiotic release in vitro are discussed.
4.1. Effect of L/P and antibiotic on cement microstructure and properties
4.1.1. Setting time
It has been reported that the setting time of cement for orthopaedic
applications should be within the 10–40 min range [16]. In the present
study, the setting time determined for the reference and SF-loaded ce-
ments exceed this range for any L/P ratio tested, but, interestingly, it de-
creased when SF was introduced into the cement formulation;
furthermore, this decrease can be further enhanced when the well-
known CPC setting-time promoter, disodium hydrogen phosphate
(Table 3), is also dissolved in the liquid phase (SF aqueous solution)
used to prepare the paste.
Several authors have shown, on the contrary, that the incorporation
of an antibiotic in phosphocalcic cement formulations generally delayed
the setting time [6,17–22]; this effect was attributed to the interaction
of the drug with the cement mineral matrix during the cement setting
reaction. It shall be considered, however, that physical setting times, de-
termined using Gilmore needles, and the chemical setting times,
estimated through the advancement of the setting reaction, are two pa-
rameters that are not connected by simple relationships. The mode of
interaction of the fusidate ions with the cement constituents was not
elucidated in this study, although, the formation of insoluble amor-
phous calcium fusidate seemed to be possible. Thus, the preliminary re-
sults on SF interactions with calcium phosphate materials and cements
(data not shown) revealed that, in the range of concentration investi-
gated (0–0.21mM), the antibiotic exhibited a high afﬁnity for themine-
ral surface, and for higher drug contents the possible formation of a
complex involving fusidate molecules and matrix mineral ions could
not be discarded.
4.1.2. Injectability
Several studies have indicated the effect of the L/P ratio, not only on
the rheological properties of the cement paste, but also on its porosity
[23]. The main concern for the implementation of bonemineral cement
using minimally invasive surgery techniques (including a syringe sys-
tem) is related to the ﬁlter-pressing phenomenon, also called the
phase-separation phenomenon (i.e., a pastewith a higher L/P ratio is ex-
truded ﬁrst and then the L/P ratio of the extruded paste decreases) [24],
which leads to a heterogeneous composition of the extruded paste andalso to an increase in the extrusion load, over the limit of manual extru-
sion (considered as 12 kg). The present study demonstrated that the
injectability of SF-loaded cement paste is higher than that of the refer-
ence cement; in addition, the ﬁlter-pressing phenomenon can be
avoided by combining a L/P ratio of 0.8 with a SF load. An analogous be-
haviour has been revealed for another CPC loadedwith another antibio-
tic, that is, cephalexin; the authors suggested a lubricating effect of the
antibiotic, favouring the extrusion of the CPC suspension [6]. Regarding
the effect of the L/P ratio on themineral cement injectability, our results
are in agreement with the data reported by many authors [2,25–26]. In
addition, the improvement in the injectability with the additive can be
related to the high water solubility of sodium fusidate, which can in-
crease the viscosity of the liquid phase (SF solution) and, thus, the cohe-
sion of the paste that, in turn, facilitates its homogeneous extrusion. The
improvement of the paste cohesion has been noticed when preparing
the cement paste using SF solution compared to the paste prepared
using only water.4.1.3. Mechanical properties
Several studies have reported the effect of the introduction of an an-
tibiotic on the mechanical properties of CPC, especially their compres-
sive strength, which is more or less altered depending on the
concentration of the drug [4,9,17,22–23,27–28]. This decrease in com-
pressive strength can be attributed to several factors, such as an increase
in cement porosity or the interaction of the drug with the reactive ce-
ment powders, which could inhibit the setting reaction [29].
Fig. 7. Cumulated fusidate released (%) from cements prepared with an L/P ratio of 0.7 or
0.8.
Table 3
Initial and ﬁnal setting times of SF-loaded cements (CSF) prepared with L/P = 0.7 and a
liquid phase including different amounts of dissolved disodium hydrogen phosphate (0–
0.5 M).
Concentration of
Na2HPO4
Initial setting time (tI)
(min)
Final setting time (tF)
(min)
CSF7 CSF7
0 50 ± 2 105 ± 3
0.25 M 34 ± 1 76 ± 1
0.5 M 25 ± 1 52 ± 2In the present study, we showed that the introduction of sodium
fusidate leads to a decrease in the total porosity of the cement, which
did not improve the cement compressive strength. However the com-
pressive strength noted for the reference or SF-loaded cements remains
close to 9 MPa, corresponding to trabecular bone [30].4.1.4. Porosity
Porosity is a key factor affecting mechanical properties of cement as
well as its biological properties. The pore size and interconnection can
control cell activity. CPCs are intrinsically mesoporous and this porosity
is mainly related to the L/P ratio. A high porosity can alter the mecha-
nical properties; however it could also enable the penetration of biolog-
icalﬂuids, vessels and cells, favouringmaterial resorption and boneneo-
formation.
In the case of SF-loaded cement, a decrease in porosity without an
improvement in cement compressive strength was observed. We can
hypothesise that the consumption of water during the cement setting
reaction and water elimination upon cement drying lowered the
amount of water available to keep the SF solubilised; when the solubi-
lity limitwas reached, the SF could precipitatewithin the pores. Another
hypothesis could be related to the precipitation of calcium fusidate
within the pores; however, FTIR spectroscopy and XRD analyses could
not allow distinguishing calcium fusidate from sodium fusidate (data
not presented). Furthermore, it appears that the smaller pores (around
15 nm in diameter) are mainly affected by the decrease in porosity for
SF-loaded cement; the proportion of pores with nanometric sizes was
lowered, because they were ﬁlled with the antibiotic (as sodium and/
or calcium fusidate).Fig. 8.Amount of fusidate released per day from cements prepared with an L/P ratio of 0.7
or 0.8.The results of this study conﬁrmed that, not only the amount of
water (L/P ratio), but also the presence of sodium fusidate were deter-
minant parameters for the cement microstructure.
4.2. Antibiotic release kinetics and mechanism
To identify the mechanisms that govern the release of the antibiotic
from the cement, the release data were analysed using several models
[31].
Korsmeyer and Peppas developed a simple, semi-empirical model,
relating drug releasewith the time elapsed, according to Eq. (1) [32,33]:
Q ¼Mt=M∞ ¼ ktn ð1Þ
where t is the release time (min), Q (or Mt./M∞) is the fraction of drug
released, k is a kinetic constant, and the diffusional exponent, n, gives
an indication of the drug-release mechanism with limits depending in
the geometry of the release device; values of n below 0.5 correspond
to Fickian diffusion, whereas values from 0.5 to 1.0 are attributed to
non-Fickian transport (i.e. a mixed diffusion and erosion mechanisms).
Higuchi developed several theoretical models to study drug release
[34]. In summary, a simpliﬁed Higuchi model can be expressed as
Eq. (2):
Q ¼Mt=M∞ ¼ at0:5 ð2Þ
where t is the release time, Mt. is the amount of drug released at time t,
M∞ is the total amount of drug released, and a is the Higuchi diffusion
constant. This model showed good correlation to the release proﬁles,
in which the predominant mechanism is simple Fickian diffusion.
The Kopchamodel can be used to quantify the contributions of diffu-
sion (A) and erosion (B). [35]. This model is described by Eq. (3):
Mt ¼ A
ﬃﬃ
t
p
þ Bt ð3Þ
whereMt is the amount of drug released at time t, A is a diffusional term
and B is the erosional term. The diffusion phenomenon is predominant
when A/B N 1.
To determine the constants, the experimental SF release data (Fig. 7)
were ﬁtted with the three models presented (i.e. Eqs. (1), (2) and (3).
The parameters obtained after ﬁtting the SF release data with each
model are reported in Table 4. Examining these parameters suggests
that, regardless of the L/P used, the mechanisms involved in the release
of sodium fusidate were mainly owing to diffusion process. Indeed
values of n lower than 0.5 for the Korsmeyer–Peppas model indicated
that the release followed Fick's law. In addition, A/B ratios higher thanTable 4
Parameters of the SF release proﬁle ﬁtting, according to the different models.
Higuchi Korsmeyer–Peppas Kopcha
a r2 n r2 A/B r2
CSF7 0.600 0.970 0.36 0.988 ≫1 0.970
CSF8 0.992 0.986 0.40 0.993 ≫1 0.992
Table 5
Total porosity andmicroporosity of reference (CR) and SF-loaded (CSF) cements (L/P ratio
= 0.7) before and after 34 days of release testing.
Reference cement
(CR), L/P = 0.7
Sodium fusidate-loaded
cement (CSF), L/P = 0.7
Before After Before After
Total porosity (%)
[5 nm–300 μm]
74 ± 2 74 ± 1 69 ± 1 72 ± 1
Submicron porosity (%)
[5 nm–2 μm]
70 ± 2 71 ± 2 63 ± 2 70 ± 21 (obtained by considering the Kopchamodel) conﬁrmed that diffusion
was the determinant phenomenon for SF drug release from the studied
cements. Moreover, the release rate constants for the Higuchi model
showed that increasing the L/P ratio used to prepare the cements caused
an increase in the speed of release. The release is directly linked to the
porosity of cement and especially to the ability of a cement to favour
the diffusion phenomenon.
It is important to note that the in vitro release test was performed at
physiological pH and temperature, but in the absence of macrophage
cells. Under these conditions, the erosion process can only occur by
chemical dissolution of the cement in buffer solution, and this phenom-
enon is considered to be very low.When implanted, the biological activ-
ity of cells shall favour cement resorption and, consequently, enhance
the release of the antibiotic.
Our study showed that, irrespective of the L/P ratio, a burst release of
fusidate (3–10 mg/day) was followed by a sustained daily release of SF
(1–2 mg/day) over the next 30 days. The amount of drug released
during the ﬁrst stage of release kinetics can ensure the loading dose,
whereas, after few days, the amount released can be considered as a
maintenance dose.
It has been shown in the literature that fusidic acid concentrations be-
tween 0.03 and 0.12 mg/L inhibit the growth of most of staphylococcusFig. 9. Pore-size distribution of cements, prepared with an L/P ratio of 0.7, before and after
the release test: (a) reference cement (CR7) and (b) SF-loaded cement (CSF7).strains [14,36–38]; however, for Staphylococcus aureus that is resistant
to methicillin (SARM), the minimum inhibitory concentrations (MICs)
are slightly higher (0.03–0.8 mg/L).
If we compare the evolution of the porosity of the reference and
antibiotic-loaded cements before and after the release test (Table 5),
we note an increase in the total porosity after 34 days of testing only
for SF-loaded cement, suggesting that the dissolution and the release
of the antibiotic created a secondary porosity in addition to the existing
porous volume of the cement before the in vitro release tests. Examina-
tion of the pore-size distribution of the reference and SF-loaded ce-
ments before and after release testing (Fig. 9) revealed that the
immersion of the reference material into the solution for 34 days
induces a slight increase in pore size and the apparition of a secondary
porosity domain. Thismodiﬁcation of reference cement pore-size distri-
bution during immersion could be due to the evolution of its chemical
composition (vaterite, which is metastable in aqueous solution, could
partly dissolve during the release testing) as well as crystals organisa-
tion in cement matrix. Concerning the drug-containing cement, the po-
rosities obtained after release testing highlight an increase in the total
porosity with modiﬁcation of the porous network. The dissolution and
release of sodium fusidate induce secondary porosity, owing to the dis-
appearance of drug crystals.
5. Conclusion
This study shows the determinant role of water (L/P ratio) and the
presence of the drug on calcium carbonate–calcium phosphate biomi-
metic cement properties (especially cement paste injectability) andmi-
crostructure, which, in turn, control the diffusion of the antibiotic and,
consequently, its release rate. Based on the in vitro release study, this
local antibiotic delivery bone-substitute material could ensure the de-
livery of a loading dose (3–10 mg/day) for the ﬁrst 2 days after surgery
and then a maintenance dose (1–2 mg/day) for more than 1 month,
making this SF-loaded cement a promising candidate as a local antibiot-
ic delivery bone-substitute material, especially for the prevention of
bone-implant-associated infections.
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